New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTTGTX, LGNDLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
09:15 EDTLGNDLigand management to meet with Craig Hallum
Meeting to be held in Kansas City on May 28 hosted by Craig Hallum.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use